Company: LIDRW
Filing Date: 2025-07-28
Form Type: 8-K
Source: 0000947871-25-000693
Chunk: 0

Company: AEye, Inc.
Filing Date: 2025-07-28
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01.      Other Events.  

On July 28, 2025, AEye, Inc. (the
“ Company”) filed the Amendment No.4 (the “ Amendment No. 4”) to the Prospectus Supplements (as defined below) to
update the maximum number of shares of the Company’s common stock (the “ Placement Shares”) issuable pursuant to the
At Market Issuance Sales Agreement between the Company and A. G. P./Alliance Global Partners, dated September 12, 2024 (the “ Sales
Agreement”), to up to an aggregate of $75,000,000 of Placement Shares, which includes the shares of the Company’s common stock
having an aggregate gross sales price of approximately $23,724,958 that were sold pursuant to the Prospectus Supplements to date

The
issuance and sale of the PlacementShares by the Company under the Sales Agreement
will be made pursuant to the Company’s registration statement on Form S-3 (File No. 333-274546) filed with the Securities and Exchange
Commission on September 15, 2023, and declared effective on September 26, 2023, as supplemented and amended by the prospectus supplements,
dated as of September 13, 2024 and December 30, 2024 (the “ Prospectus Supplements”), the Amendments No.1, No. 2 and No. 3
to the Prospectus Supplements, dated as of January 7, 2025, January 23, 2025 and July 25, 2025, respectively, and the Amendment No 4.

A
copy of the legal opinion of Allen Overy Shearman Sterling US LLP relating to the Placement Shares is filed as Exhibit 5.1 hereto.

This Current Report on Form 8-K shall not constitute
an offer to sell or a solicitation of an offer to buy any shares of common stock in any state or jurisdiction in which such an offer,
solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.